Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Hepatic and neuronal phenotype of NPC1-/- mice.

Santiago-Mujica E, Flunkert S, Rabl R, Neddens J, Loeffler T, Hutter-Paier B.

Heliyon. 2019 Mar 14;5(3):e01293. doi: 10.1016/j.heliyon.2019.e01293. eCollection 2019 Mar.

2.

Metabolic disease and ABHD6 alter the circulating bis(monoacylglycerol)phosphate profile in mice and humans.

Grabner GF, Fawzy N, Pribasnig MA, Trieb M, Taschler U, Holzer M, Schweiger M, Wolinski H, Kolb D, Horvath A, Breinbauer R, Rülicke T, Rabl R, Lass A, Stadlbauer V, Hutter-Paier B, Stauber RE, Fickert P, Zechner R, Marsche G, Eichmann TO, Zimmermann R.

J Lipid Res. 2019 May;60(5):1020-1031. doi: 10.1194/jlr.M093351. Epub 2019 Mar 20.

3.

BACE1-cleavage of Sez6 and Sez6L is elevated in Niemann-Pick type C disease mouse brains.

Causevic M, Dominko K, Malnar M, Vidatic L, Cermak S, Pigoni M, Kuhn PH, Colombo A, Havas D, Flunkert S, McDonald J, Gunnersen JM, Hutter-Paier B, Tahirovic S, Windisch M, Krainc D, Lichtenthaler SF, Hecimovic S.

PLoS One. 2018 Jul 6;13(7):e0200344. doi: 10.1371/journal.pone.0200344. eCollection 2018.

4.

Phosphorylation of different tau sites during progression of Alzheimer's disease.

Neddens J, Temmel M, Flunkert S, Kerschbaumer B, Hoeller C, Loeffler T, Niederkofler V, Daum G, Attems J, Hutter-Paier B.

Acta Neuropathol Commun. 2018 Jun 29;6(1):52. doi: 10.1186/s40478-018-0557-6.

5.

mTh1 driven expression of hTDP-43 results in typical ALS/FTLD neuropathological symptoms.

Scherz B, Rabl R, Flunkert S, Rohler S, Neddens J, Taub N, Temmel M, Panzenboeck U, Niederkofler V, Zimmermann R, Hutter-Paier B.

PLoS One. 2018 May 22;13(5):e0197674. doi: 10.1371/journal.pone.0197674. eCollection 2018.

6.

Development of GMP-1 a molecular chaperone network modulator protecting mitochondrial function and its assessment in fly and mice models of Alzheimer's disease.

Pavlov PF, Hutter-Paier B, Havas D, Windisch M, Winblad B.

J Cell Mol Med. 2018 Jul;22(7):3464-3474. doi: 10.1111/jcmm.13624. Epub 2018 Apr 27.

7.

Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer's Disease.

Kutzsche J, Schemmert S, Tusche M, Neddens J, Rabl R, Jürgens D, Brener O, Willuweit A, Hutter-Paier B, Willbold D.

Molecules. 2017 Oct 10;22(10). pii: E1693. doi: 10.3390/molecules22101693.

8.

SEN1500, a novel oral amyloid-β aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer's disease.

Brunner D, Flunkert S, Neddens J, Duller S, Scopes DIC, Treherne JM, Hutter-Paier B.

Neurosci Lett. 2017 Nov 1;660:96-102. doi: 10.1016/j.neulet.2017.09.028. Epub 2017 Sep 14.

PMID:
28917978
9.

Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form.

Collier TJ, Srivastava KR, Justman C, Grammatopoulous T, Hutter-Paier B, Prokesch M, Havas D, Rochet JC, Liu F, Jock K, de Oliveira P, Stirtz GL, Dettmer U, Sortwell CE, Feany MB, Lansbury P, Lapidus L, Paumier KL.

Neurobiol Dis. 2017 Oct;106:191-204. doi: 10.1016/j.nbd.2017.07.007. Epub 2017 Jul 12.

10.

Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease-Studies on Relation to Effective Target Occupancy.

Hoffmann T, Meyer A, Heiser U, Kurat S, Böhme L, Kleinschmidt M, Bühring KU, Hutter-Paier B, Farcher M, Demuth HU, Lues I, Schilling S.

J Pharmacol Exp Ther. 2017 Jul;362(1):119-130. doi: 10.1124/jpet.117.240614. Epub 2017 Apr 26.

PMID:
28446518
11.

Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice.

Rabl R, Breitschaedel C, Flunkert S, Duller S, Amschl D, Neddens J, Niederkofler V, Rockenstein E, Masliah E, Roemer H, Hutter-Paier B.

BMC Neurosci. 2017 Jan 31;18(1):22. doi: 10.1186/s12868-017-0341-8.

12.

Early and progressive microstructural brain changes in mice overexpressing human α-Synuclein detected by diffusion kurtosis imaging.

Khairnar A, Ruda-Kucerova J, Szabó N, Drazanova E, Arab A, Hutter-Paier B, Neddens J, Latta P, Starcuk Z Jr, Rektorova I.

Brain Behav Immun. 2017 Mar;61:197-208. doi: 10.1016/j.bbi.2016.11.027. Epub 2016 Dec 5.

PMID:
27923670
13.

Quantitative evaluation of orofacial motor function in mice: The pasta gnawing test, a voluntary and stress-free behavior test.

Rabl R, Horvath A, Breitschaedel C, Flunkert S, Roemer H, Hutter-Paier B.

J Neurosci Methods. 2016 Dec 1;274:125-130. doi: 10.1016/j.jneumeth.2016.10.006. Epub 2016 Oct 13.

14.

Decreased Plasma Aβ in Hyperlipidemic APPSL Transgenic Mice Is Associated with BBB Dysfunction.

Löffler T, Flunkert S, Temmel M, Hutter-Paier B.

Front Neurosci. 2016 Jun 1;10:232. doi: 10.3389/fnins.2016.00232. eCollection 2016.

15.

Brain cortical cholesterol metabolism is highly affected by human APP overexpression in mice.

Löffler T, Schweinzer C, Flunkert S, Sántha M, Windisch M, Steyrer E, Hutter-Paier B.

Mol Cell Neurosci. 2016 Jul;74:34-41. doi: 10.1016/j.mcn.2016.03.004. Epub 2016 Mar 21.

PMID:
27013422
16.

Late-stage α-synuclein accumulation in TNWT-61 mouse model of Parkinson's disease detected by diffusion kurtosis imaging.

Khairnar A, Ruda-Kucerova J, Drazanova E, Szabó N, Latta P, Arab A, Hutter-Paier B, Havas D, Windisch M, Sulcova A, Starcuk Z Jr, Király A, Rektorova I.

J Neurochem. 2016 Mar;136(6):1259-1269. doi: 10.1111/jnc.13500. Epub 2016 Feb 1.

17.

Diffusion Kurtosis Imaging Detects Microstructural Alterations in Brain of α-Synuclein Overexpressing Transgenic Mouse Model of Parkinson's Disease: A Pilot Study.

Khairnar A, Latta P, Drazanova E, Ruda-Kucerova J, Szabó N, Arab A, Hutter-Paier B, Havas D, Windisch M, Sulcova A, Starcuk Z Jr, Rektorova I.

Neurotox Res. 2015 Nov;28(4):281-9. doi: 10.1007/s12640-015-9537-9. Epub 2015 Jul 8.

PMID:
26153486
18.

Influence of Lentiviral β-Synuclein Overexpression in the Hippocampus of a Transgenic Mouse Model of Alzheimer's Disease on Amyloid Precursor Protein Metabolism and Pathology.

Krassnig S, Schweinzer C, Taub N, Havas D, Auer E, Flunkert S, Schreibmayer W, Hutter-Paier B, Windisch M.

Neurodegener Dis. 2015;15(4):243-57. doi: 10.1159/000430952. Epub 2015 Jun 25.

PMID:
26111745
20.

Multigram synthesis and in vivo efficacy studies of a novel multitarget anti-Alzheimer's compound.

Sola I, Viayna E, Gómez T, Galdeano C, Cassina M, Camps P, Romeo M, Diomede L, Salmona M, Franco P, Schaeffer M, Colantuono D, Robin D, Brunner D, Taub N, Hutter-Paier B, Muñoz-Torrero D.

Molecules. 2015 Mar 10;20(3):4492-515. doi: 10.3390/molecules20034492.

21.

L-type calcium channel blockers and substance P induce angiogenesis of cortical vessels associated with beta-amyloid plaques in an Alzheimer mouse model.

Daschil N, Kniewallner KM, Obermair GJ, Hutter-Paier B, Windisch M, Marksteiner J, Humpel C.

Neurobiol Aging. 2015 Mar;36(3):1333-41. doi: 10.1016/j.neurobiolaging.2014.12.027. Epub 2014 Dec 31.

22.

Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.

Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, Saeed F, Wostein H, Walko T 3rd, Vaswani A, Wardius M, Syed Z, Ravenscroft J, Mozzoni K, Silky C, Rehak C, Yurko R, Finn P, Look G, Rishton G, Safferstein H, Miller M, Johanson C, Stopa E, Windisch M, Hutter-Paier B, Shamloo M, Arancio O, LeVine H 3rd, Catalano SM.

PLoS One. 2014 Nov 12;9(11):e111898. doi: 10.1371/journal.pone.0111898. eCollection 2014.

23.

Neuroinflammation and related neuropathologies in APPSL mice: further value of this in vivo model of Alzheimer's disease.

Löffler T, Flunkert S, Havas D, Schweinzer C, Uger M, Windisch M, Steyrer E, Hutter-Paier B.

J Neuroinflammation. 2014 May 1;11:84. doi: 10.1186/1742-2094-11-84.

24.

CaV1.2 calcium channel expression in reactive astrocytes is associated with the formation of amyloid-β plaques in an Alzheimer's disease mouse model.

Daschil N, Obermair GJ, Flucher BE, Stefanova N, Hutter-Paier B, Windisch M, Humpel C, Marksteiner J.

J Alzheimers Dis. 2013;37(2):439-51. doi: 10.3233/JAD-130560.

25.

Commentary to the recently published review "Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease" by Li, Evrahimi and Schluesener. Ageing Res. Rev. 2013 Jan;12(1):116-40.

Windisch M, Flunkert S, Havas D, Hutter-Paier B.

Ageing Res Rev. 2013 Sep;12(4):852-4. doi: 10.1016/j.arr.2013.06.006. Epub 2013 Jul 10.

PMID:
23851053
26.

The bivalent ligand approach as a tool for improving the in vitro anti-Alzheimer multitarget profile of dimebon.

Rosini M, Simoni E, Bartolini M, Soriano E, Marco-Contelles J, Andrisano V, Monti B, Windisch M, Hutter-Paier B, McClymont DW, Mellor IR, Bolognesi ML.

ChemMedChem. 2013 Aug;8(8):1276-81. doi: 10.1002/cmdc.201300263. Epub 2013 Jul 3. No abstract available.

PMID:
23824986
27.

Impact of ApoB-100 expression on cognition and brain pathology in wild-type and hAPPsl mice.

Löffler T, Flunkert S, Havas D, Sántha M, Hutter-Paier B, Steyrer E, Windisch M.

Neurobiol Aging. 2013 Oct;34(10):2379-88. doi: 10.1016/j.neurobiolaging.2013.04.008. Epub 2013 May 3.

PMID:
23643485
28.

Non-selective calcium channel blocker bepridil decreases secondary pathology in mice after photothrombotic cortical lesion.

Lipsanen A, Flunkert S, Kuptsova K, Hiltunen M, Windisch M, Hutter-Paier B, Jolkkonen J.

PLoS One. 2013;8(3):e60235. doi: 10.1371/journal.pone.0060235. Epub 2013 Mar 26.

29.

In vivo and ex vivo imaging of amyloid-β cascade aggregates with a Pronucleon™ peptide.

Nyborg AC, Moll JR, Wegrzyn RD, Havas D, Hutter-Paier B, Feuerstein GG, Rudolph AS.

J Alzheimers Dis. 2013;34(4):957-67. doi: 10.3233/JAD-122107.

PMID:
23321523
30.

Time course and progression of wild type α-synuclein accumulation in a transgenic mouse model.

Amschl D, Neddens J, Havas D, Flunkert S, Rabl R, Römer H, Rockenstein E, Masliah E, Windisch M, Hutter-Paier B.

BMC Neurosci. 2013 Jan 9;14:6. doi: 10.1186/1471-2202-14-6.

31.

Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice.

Rogers K, Felsenstein KM, Hrdlicka L, Tu Z, Albayya F, Lee W, Hopp S, Miller MJ, Spaulding D, Yang Z, Hodgdon H, Nolan S, Wen M, Costa D, Blain JF, Freeman E, De Strooper B, Vulsteke V, Scrocchi L, Zetterberg H, Portelius E, Hutter-Paier B, Havas D, Ahlijanian M, Flood D, Leventhal L, Shapiro G, Patzke H, Chesworth R, Koenig G.

Mol Neurodegener. 2012 Dec 18;7:61. doi: 10.1186/1750-1326-7-61.

32.

Elevated levels of soluble total and hyperphosphorylated tau result in early behavioral deficits and distinct changes in brain pathology in a new tau transgenic mouse model.

Flunkert S, Hierzer M, Löffler T, Rabl R, Neddens J, Duller S, Schofield EL, Ward MA, Posch M, Jungwirth H, Windisch M, Hutter-Paier B.

Neurodegener Dis. 2013;11(4):194-205. doi: 10.1159/000338152. Epub 2012 Jul 10.

PMID:
22797329
33.

Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.

Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, Rönicke R, Reymann K, Hutter-Paier B, Alexandru A, Jagla W, Graubner S, Glabe CG, Demuth HU, Bloom GS.

Nature. 2012 May 2;485(7400):651-5. doi: 10.1038/nature11060.

34.

Stable mutated tau441 transfected SH-SY5Y cells as screening tool for Alzheimer's disease drug candidates.

Löffler T, Flunkert S, Taub N, Schofield EL, Ward MA, Windisch M, Hutter-Paier B.

J Mol Neurosci. 2012 May;47(1):192-203. doi: 10.1007/s12031-012-9716-6. Epub 2012 Feb 19.

35.

A longitudinal study of behavioral deficits in an AβPP transgenic mouse model of Alzheimer's disease.

Havas D, Hutter-Paier B, Ubhi K, Rockenstein E, Crailsheim K, Masliah E, Windisch M.

J Alzheimers Dis. 2011;25(2):231-43. doi: 10.3233/JAD-2011-101866.

36.

The γ-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer's disease.

Lanzillotta A, Sarnico I, Benarese M, Branca C, Baiguera C, Hutter-Paier B, Windisch M, Spano P, Imbimbo BP, Pizzi M.

J Mol Neurosci. 2011 Sep;45(1):22-31. doi: 10.1007/s12031-010-9482-2. Epub 2010 Dec 22.

PMID:
21181298
37.

The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice.

Huttunen HJ, Havas D, Peach C, Barren C, Duller S, Xia W, Frosch MP, Hutter-Paier B, Windisch M, Kovacs DM.

J Neuropathol Exp Neurol. 2010 Aug;69(8):777-88. doi: 10.1097/NEN.0b013e3181e77ed9.

38.

Comparison of pharmacological modulation of APP metabolism in primary chicken telencephalic neurons and in a human neuroglioma cell line.

Czvitkovich S, Duller S, Mathiesen E, Lorenzoni K, Imbimbo BP, Hutter-Paier B, Windisch M, Wronski R.

J Mol Neurosci. 2011 Mar;43(3):257-67. doi: 10.1007/s12031-010-9416-z. Epub 2010 Jul 6.

39.

Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model.

Corcoran NM, Martin D, Hutter-Paier B, Windisch M, Nguyen T, Nheu L, Sundstrom LE, Costello AJ, Hovens CM.

J Clin Neurosci. 2010 Aug;17(8):1025-33. doi: 10.1016/j.jocn.2010.04.020. Epub 2010 May 26.

PMID:
20537899
40.

L-type calcium channel CaV 1.2 in transgenic mice overexpressing human AbetaPP751 with the London (V717I) and Swedish (K670M/N671L) mutations.

Willis M, Kaufmann WA, Wietzorrek G, Hutter-Paier B, Moosmang S, Humpel C, Hofmann F, Windisch M, Knaus HG, Marksteiner J.

J Alzheimers Dis. 2010;20(4):1167-80. doi: 10.3233/JAD-2010-091117.

PMID:
20413896
41.

Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism.

Giorgetti M, Gibbons JA, Bernales S, Alfaro IE, Drieu La Rochelle C, Cremers T, Altar CA, Wronski R, Hutter-Paier B, Protter AA.

J Pharmacol Exp Ther. 2010 Jun;333(3):748-57. doi: 10.1124/jpet.109.164491. Epub 2010 Mar 1.

PMID:
20194526
42.

Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway.

Huttunen HJ, Peach C, Bhattacharyya R, Barren C, Pettingell W, Hutter-Paier B, Windisch M, Berezovska O, Kovacs DM.

FASEB J. 2009 Nov;23(11):3819-28. doi: 10.1096/fj.09-134999. Epub 2009 Jul 22.

43.

CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.

Imbimbo BP, Hutter-Paier B, Villetti G, Facchinetti F, Cenacchi V, Volta R, Lanzillotta A, Pizzi M, Windisch M.

Br J Pharmacol. 2009 Mar;156(6):982-93. doi: 10.1111/j.1476-5381.2008.00097.x.

44.

Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology.

Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Jagla W, Schlenzig D, Lindner C, Rudolph T, Reuter G, Cynis H, Montag D, Demuth HU, Rossner S.

Nat Med. 2008 Oct;14(10):1106-11. doi: 10.1038/nm.1872. Epub 2008 Sep 28.

PMID:
18836460
45.

Chromogranin B and Secretogranin II in transgenic mice overexpressing human APP751 with the London (V717I) and Swedish (K670M/N671L) mutations and in Alzheimer patients.

Willis M, Prokesch M, Hutter-Paier B, Windisch M, Stridsberg M, Mahata SK, Kirchmair R, Wietzorrek G, Knaus HG, Jellinger K, Humpel C, Marksteiner J.

J Alzheimers Dis. 2008 Mar;13(2):123-35.

PMID:
18376054
46.

The role of alpha-synuclein in neurodegenerative diseases: a potential target for new treatment strategies?

Windisch M, Wolf H, Hutter-Paier B, Wronski R.

Neurodegener Dis. 2008;5(3-4):218-21. doi: 10.1159/000113707. Epub 2008 Mar 6. Review.

PMID:
18322395
47.

Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?

Windisch M, Wolf HJ, Hutter-Paier B, Wronski R.

Curr Alzheimer Res. 2007 Dec;4(5):556-61. Review.

PMID:
18220522
48.

Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?

Windisch M, Wolf HJ, Hutter-Paier B, Hofmeister A, Wronski R.

Curr Alzheimer Res. 2007 Sep;4(4):446-57. Review.

PMID:
17908049
49.

Localization and expression of substance P in transgenic mice overexpressing human APP751 with the London (V717I) and Swedish (K670M/N671L) mutations.

Willis M, Hutter-Paier B, Wietzorrek G, Windisch M, Humpel C, Knaus HG, Marksteiner J.

Brain Res. 2007 Apr 27;1143:199-207. Epub 2007 Jan 30.

PMID:
17328871
50.

Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease.

Wang CY, Finstad CL, Walfield AM, Sia C, Sokoll KK, Chang TY, Fang XD, Hung CH, Hutter-Paier B, Windisch M.

Vaccine. 2007 Apr 20;25(16):3041-52. Epub 2007 Jan 19.

PMID:
17287052

Supplemental Content

Loading ...
Support Center